{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Subjects were enrolled on the first dose level (20 mg/m\\^2), following a standard 3+3 dose escalation. For any given dose level, if none of the 3 subjects developed a treatment-related dose limiting toxicity (DLT), defined per protocol, dose escalation would follow. If a DLT occurred in any given dose level, the cohort would be expanded to 6. Further dose escalation would be made only if DLTs occurred in \\<2 out of 6 subjects. If \\>=2 of 6 develop DLTs, dose de-escalation would be made to the previous level. The highest dose level at which no more than one of six participants experience a DLT defines the MTD.","groups":[{"description":"Participants in all cohorts were administered 20 mg/m\\^2 of Carfilzomib on days +1 and +2, via intravenous catheter (IV) over 30 minutes.\n\nDose Level 1, 2, 3, 4: Participants were administered 20, 27, 36, or 45 mg/m\\^2 of Carfilzomib on days +6 and +7, respectively.\n\nParticipants in all cohorts were administered tacrolimus at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.","id":"OG000","title":"Phase 1 Study Participants"}],"paramType":"NUMBER","populationDescription":"Phase 1 study participants","reportingStatus":"POSTED","timeFrame":"Up to day 28","title":"Phase I: Maximum Tolerated Dose (MTD) of Carfilzomib","type":"PRIMARY","unitOfMeasure":"milligrams per square meter (mg/m^2)"}